FIA
IPHA

FNY Investment Advisers’s Innate Pharma IPHA Stock Holding History

FNY Investment Advisers’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,795
Closed -$11K – 627
2019
Q4 		$11K Buy
+1,795
New +$11K ﹤0.01% 624

Other funds holding IPHA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

FNY Investment Advisers's IPHA Position: Q1 2020 in Review

FNY Investment Advisers sold out of Innate Pharma (IPHA) in Q1 2020, closing a stake of 1,795 shares — an estimated $11K sold.

FNY Investment Advisers first reported a position in IPHA in Q4 2019 and held it in 1 quarter. The position peaked at $11K in Q4 2019. 10 funds tracked by Wall St. Rank hold IPHA as of Q1 2020.

  • FNY Investment Advisers reported no remaining Innate Pharma position as of Q1 2020 after selling out during the quarter.
  • FNY Investment Advisers sold 1,795 Innate Pharma shares in Q1 2020, an estimated $11K.
  • FNY Investment Advisers first reported a position in Innate Pharma in Q4 2019 and held it in 1 quarter.
  • FNY Investment Advisers's Innate Pharma position peaked at $11K in Q4 2019.
  • 10 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2020.

Based on FNY Investment Advisers's 13F filing for Q1 2020, filed 9 Apr 2020.